 |
3 Diseases |  |
1 Trial |
|
1 Trial |  |
122 News |  |
| «12 |
- || AL101 / Ayala Pharma
Trial primary completion date, Metastases: Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - May 17, 2017
P1, N=110, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Mar 2017 --> Jun 2017
- || AL101 / Ayala Pharma
Combination therapy, Metastases: Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors (clinicaltrials.gov) - Apr 19, 2017
P1, N=95, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Mar 2017 --> Jun 2017 Trial primary completion date: Dec 2016 --> Jun 2017
- AL101 / Ayala Pharma
Trial primary completion date: Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Mar 29, 2017
P1, N=42, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Dec 2016 --> Jun 2017 Trial primary completion date: Jun 2017 --> Oct 2017
- AL101 / Ayala Pharma
Trial primary completion date: Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Mar 1, 2017
P1, N=42, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Jun 2017 --> Oct 2017 Trial primary completion date: Dec 2016 --> Jun 2017
- || AL101 / Ayala Pharma
Trial primary completion date, Metastases: Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Feb 16, 2017
P1, N=110, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Dec 2016 --> Jun 2017 Trial primary completion date: Oct 2016 --> Mar 2017
- AL101 / Ayala Pharma
Trial primary completion date: Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Oct 11, 2016
P1, N=42, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Oct 2016 --> Mar 2017 Trial primary completion date: Nov 2015 --> Dec 2016
- AL101 / Ayala Pharma
Trial primary completion date: Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Sep 8, 2016
P1, N=42, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Nov 2015 --> Dec 2016 Trial primary completion date: Dec 2016 --> Nov 2015
- AL101 / Ayala Pharma
Trial primary completion date: Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Aug 16, 2016
P1, N=42, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Dec 2016 --> Nov 2015 Trial primary completion date: Jun 2016 --> Dec 2016
- || AL101 / Ayala Pharma
Trial primary completion date, Metastases: Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - May 25, 2016
P1, N=110, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Jun 2016 --> Dec 2016 Trial primary completion date: Apr 2016 --> Oct 2016
- AL101 / Ayala Pharma
Enrollment closed: Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Jan 26, 2016
P1, N=42, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Apr 2016 --> Oct 2016 Recruiting --> Active, not recruiting
- || AL101 / Ayala Pharma
Enrollment closed, Metastases: Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Jan 26, 2016
P1, N=110, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || AL101 / Ayala Pharma
Combination therapy, Metastases: Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors (clinicaltrials.gov) - Jan 25, 2016
P1, N=95, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- AL101 / Ayala Pharma
Trial primary completion date: Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Nov 9, 2015
P1, N=42, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2016 --> Jun 2016
- || AL101 / Ayala Pharma
Combination therapy, Metastases: Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors (clinicaltrials.gov) - Feb 9, 2015
P1, N=95, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Mar 2016 --> Jun 2016 Trial primary completion date: Jun 2015 --> Dec 2016
- AL101 / Ayala Pharma
Trial primary completion date: Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Feb 9, 2015
P1, N=42, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Jun 2015 --> Dec 2016 Trial primary completion date: Mar 2015 --> Mar 2016
- || AL101 / Ayala Pharma
Trial primary completion date, Metastases: Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Feb 9, 2015
P1, N=110, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Mar 2015 --> Mar 2016 Trial primary completion date: Feb 2015 --> Apr 2016
- || AL101 / Ayala Pharma
Combination therapy, Metastases: Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors (clinicaltrials.gov) - May 22, 2014
P1, N=96, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Feb 2015 --> Apr 2016 N=60 --> 96
- AL101 / Ayala Pharma
Trial primary completion date: Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - May 6, 2014
P1, N=42, Recruiting, Sponsor: Bristol-Myers Squibb
N=60 --> 96 Trial primary completion date: Sep 2014 --> Mar 2015
- AL101 / Ayala Pharma
Trial completion date: Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - May 6, 2014
P1, N=42, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Sep 2014 --> Mar 2015 Trial completion date: Sep 2014 --> Mar 2015
- || AL101 / Ayala Pharma
Combination therapy, Metastases: Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors (clinicaltrials.gov) - Mar 27, 2013
P1, N=60, Recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Sep 2014 --> Mar 2015 Initiation date: Jan 2012 --> Oct 2012
- ||| AL101 / Ayala Pharma
Combination therapy, Metastases: Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors (clinicaltrials.gov) - Jan 31, 2013
P1, N=60, Recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Jan 2012 --> Oct 2012 Not yet recruiting --> Recruiting
- AL101 / Ayala Pharma
Enrollment change: Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Aug 20, 2012
P1, N=42, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting N=30 --> 42
- ||| AL101 / Ayala Pharma
New P1 trial, Combination therapy, Metastases: Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors (clinicaltrials.gov) - Jul 29, 2012
P1, N=60, Recruiting, Sponsor: Bristol-Myers Squibb
- ||| AL101 / Ayala Pharma
Enrollment open, Metastases: Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Jun 24, 2012
P1, N=95, Recruiting, Sponsor: Bristol-Myers Squibb
N=30 --> 42 Active, not recruiting --> Recruiting
- AL101 / Ayala Pharma
Enrollment open: Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Oct 16, 2011
P1, N=42, Recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting